Truseltiq Side Effects
Generic name: infigratinib
Medically reviewed by Drugs.com. Last updated on Feb 24, 2024.
Note: This document provides detailed information about Truseltiq Side Effects associated with infigratinib. Some dosage forms listed on this page may not apply specifically to the brand name Truseltiq.
Applies to infigratinib: oral capsule.
Important warnings
This medicine can cause some serious health issues
Follow all directions on the label and package.
Use exactly as directed.
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
-
eye pain or discomfort;
-
vision changes;
-
redness, swelling, pain, or blisters on the palms of your hands or the soles of your feet;
-
numbness, or tingling around your mouth;
-
muscle cramps;
-
high calcium levels--confusion, tiredness, nausea, vomiting, loss of appetite, constipation, increased thirst or urination, weight loss; or
-
low blood cell counts--fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath.
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common side effects may include:
-
dry eyes, blurred vision;
-
redness or tenderness on your hands or feet;
-
dry skin, hair loss, changes in your eyelashes;
-
problems with your fingernails or toenails;
-
dry mouth, mouth sores, changes in your sense of taste;
-
stomach pain, loss of appetite, vomiting, diarrhea, constipation;
-
feeling weak or tired;
-
joint pain; or
-
low blood cell counts, high calcium, or other abnormal lab tests.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For healthcare professionals
Applies to infigratinib: oral capsule.
General adverse events
Serious adverse reactions in 2% or more patients included infections, anemia, pyrexia, abdominal pain, hypercalcemia, and sepsis. Fatal adverse reactions occurred in 1 (0.9%) patient. Adverse reactions requiring permanent discontinuation in 1% or more patients were blood creatinine increased, fatigue, subretinal fluid, and calcinosis.[Ref]
Musculoskeletal
- Very common (10% or more): Arthralgia (32%), pain in extremity (17%)
- Common (1% to 10%): Fractures[Ref]
Ocular
- Very common (10% or more): Dry eye (44%), eyelash changes (25%), blurred vision (21%), cataracts (12%)[Ref]
Metabolic
- Very common (10% or more): Increased phosphate (90%), decreased phosphate (64%), increased lipase (44%), increased calcium (43%), decreased sodium (41%), decreased calcium (10%), increased potassium (17%), decreased potassium (21%), decrease weight (15%)[Ref]
Hepatic
- Very common (10% or more): Increased triglycerides (38%), increased alkaline phosphatase (54%), increased alanine aminotransferase (51%), increased cholesterol (18%), increased bilirubin (24%), increased aspartate aminotransferase (38%), increased lipase (44%)[Ref]
Respiratory
- Very common (10% or more): Epistaxis (18%)[Ref]
Nervous system
Renal
- Very common (10% or more): Increased creatinine (93%)[Ref]
Cardiovascular
Dermatologic
- Very common (10% or more): Nail toxicity (57%), alopecia (38%), dry skin (23%), palmar-plantar erythrodysesthesia syndrome (33%)[Ref]
Gastrointestinal
- Very common (10% or more): Stomatitis (56), constipation (30%), abdominal pain (26%), dry mouth (25%), diarrhea (24%), vomiting (21%), nausea (19%), dyspepsia (17%)[Ref]
Hematologic
- Very common (10% or more): Decreased hemoglobin (53%), decrease lymphocytes (43%), decreased platelets (37%), decreased leukocytes (26%), decreased neutrophils (14%), decreased albumin (24%), increased urate (37%)[Ref]
References
1. (2021) "Product Information. Truseltiq (infigratinib)." QED Therapeutics Inc
More about Truseltiq (infigratinib)
- Check interactions
- Compare alternatives
- Imprints, shape & color data
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Truseltiq side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.